Outcomes of androgenetic alopecia treated with dutasteride mesotherapy: A case series
JAAD Case Reports · 2024-12 · 54 · 53-58
DOI: 10.1016/j.jdcr.2024.09.024 ↗Kurz gefasst
Fallbericht in der Zeitschrift JAAD Case Reports, 2024-12. Verfasst von Ambika Nohria und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Key words: alopecia; androgenetic alopecia; dutasteride; mesotherapy.Drug Administrationeapproved for the treatment of AGA in males, and dutasteride, an off-label treatment for AGA. 2 Oral dutasteride, originally approved for benign prostatic hyperplasia, may be an efficacious AGA treatment modality; however, systemic use can lead to side effects including sexual dysfunction and gynecomastia.2,3 Mesotherapy, injection of active substances directly into the scalp, has emerged as an alternative approach to administering dutasteride while limiting side effects, although this method of drug delivery is not currently approved by the US Food and Drug Administration.Despite its widespread international use, dutasteride mesotherapy remains limited in the United States.[4][5][6][7][8] This study aims to evaluate its efficacy in 10 patients. METHODSThis study is an NYU Langone Health Institutional Review Boardeapproved (i23-00157; approved March 14, 2023) retrospective analysis of 10 patients seen at NYU Langone Health dermatology.Dutasteride sterile intradermal injectable was compounded at a strength of 0.1% as a water-containing proprietary solution without propylene glycol, ethanol, dimethylsulfoxide and oil.Injections were performed with a 0.5-inch 30-gauge needle, with injections spaced 0.5 to 1 cm apart.A total of 1.25 mL of mesotherapy was injected (0.05 mL per injection) approximately every 3 months.Hair density and width were measured at the frontal scalp (12 cm from the glabella) and vertex (20-24 cm from the glabella) using the Canfield HairMetrix device.Patient charts were reviewed in Epic and relevant information was obtained from provider notes.Changes in hair density and width were compared using a t test or ManneWhitney test. RESULTSTen patients, four men and six women, received dutasteride mesotherapy.The mean age at the start of mesotherapy was 50.6 years (range, 22-80 years).All patients were receiving various concomitant topical and oral medications for AGA treatment
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York.
- University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
- Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia.
Zitieren
APA
Nohria, A., Desai, D., Páez-García, M. S., Lo Sicco, K. I., & Shapiro, J. (2024). Outcomes of androgenetic alopecia treated with dutasteride mesotherapy: A case series. JAAD Case Reports, 54, 53-58. https://doi.org/10.1016/j.jdcr.2024.09.024
Vancouver
Nohria A, Desai D, Páez-García MS, Lo Sicco KI, Shapiro J. Outcomes of androgenetic alopecia treated with dutasteride mesotherapy: A case series. JAAD Case Reports. 2024;54:53-58. doi:10.1016/j.jdcr.2024.09.024
BibTeX
@article{Nohria2024,
author = {Nohria, Ambika and Desai, Deesha and Páez-García, Maria Salomé and Lo Sicco, Kristen I and Shapiro, Jerry},
title = {Outcomes of androgenetic alopecia treated with dutasteride mesotherapy: A case series},
journal = {JAAD Case Reports},
year = {2024},
volume = {54},
pages = {53--58},
doi = {10.1016/j.jdcr.2024.09.024}
}
EUVIMED